Lisa A. Carey, MD, and Ingrid A. Mayer, MD, on Triple-Negative Breast Cancer: Treatment Challenges
2016 San Antonio Breast Cancer Symposium
Lisa A. Carey, MD, of the University of North Carolina, and Ingrid A. Mayer, MD, of the Vanderbilt-Ingram Cancer Center, discuss the current studies on neoadjuvant systemic treatment in the triple-negative disease setting.
Jame Abraham, MD, of the Cleveland Clinic, discusses findings of the Scalp Cooling Alopecia Prevention trial for patients with early-stage breast cancer (Abstract S5-02).
Sabine Linn, MD, PhD, and Sonja Vliek, MD, both of the Netherlands Cancer Institute, discuss study findings on adjuvant ibandronate in postmenopausal women with early breast cancer (Abstract S6-02).
Samuel Smith, PhD, of Queen Mary University of London, discusses study findings on menopausal symptoms as predictors of long‐term adherence in an International breast cancer intervention study (Abstract S5-03).
Jennifer A. Ligibel, MD, of Harvard Medical School, discusses the impact of preoperative exercise on breast cancer gene expression (Abstract S5-05).
Lisa A. Carey, MD, and Maki Tanioka, MD, both of the University of North Carolina, discuss study findings on weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (Abstract S3-05).